Biomarin Pharmaceutical Aktie

Kaufen
Verkaufen
62,78 EUR -0,60 EUR -0,95 %
66,15 USD +0,13 USD +0,20 %
nachbörslich
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln! Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO! Bei einem anderen Broker handeln Smartphone

Marktkap. 12 Mrd. EUR

KGV 110,19 Div. Rendite 0,00%

WKN 924801

ISIN US09061G1013

Symbol BMRN


Biomarin Pharmaceutical Aktie Analyse

14.12.18 Biomarin Pharmaceutical Outperform Wolfe Research
01.10.18 Biomarin Pharmaceutical Overweight Cantor Fitzgerald
07.08.18 Biomarin Pharmaceutical Buy Stifel, Nicolaus & Co., Inc.
03.08.18 Biomarin Pharmaceutical Buy Stifel, Nicolaus & Co., Inc.
16.05.18 Biomarin Pharmaceutical Buy Canaccord Adams
15.09.17 Biomarin Pharmaceutical Sector Perform RBC Capital Markets
14.07.17 Biomarin Pharmaceutical Outperform BMO Capital Markets
30.03.17 Biomarin Pharmaceutical Neutral UBS AG
02.03.17 Biomarin Pharmaceutical Neutral Instinet
08.12.16 Biomarin Pharmaceutical Buy Gabelli & Co
03.11.16 Biomarin Pharmaceutical Buy Deutsche Bank AG
08.04.16 Biomarin Pharmaceutical Outperform BMO Capital Markets
08.03.16 Biomarin Pharmaceutical Outperform Robert W. Baird & Co. Incorporated
03.03.16 Biomarin Pharmaceutical Buy Stifel, Nicolaus & Co., Inc.
29.02.16 Biomarin Pharmaceutical Neutral Wedbush Morgan Securities Inc.
26.02.16 Biomarin Pharmaceutical Outperform RBC Capital Markets
25.11.15 Biomarin Pharmaceutical Perform Oppenheimer & Co. Inc.
08.07.15 Biomarin Pharmaceutical Outperform RBC Capital Markets
19.06.15 Biomarin Pharmaceutical Neutral Robert W. Baird & Co. Incorporated
18.06.15 Biomarin Pharmaceutical Buy Deutsche Bank AG
18.06.15 Biomarin Pharmaceutical Buy Canaccord Adams
18.06.15 Biomarin Pharmaceutical Outperform RBC Capital Markets
05.06.15 Biomarin Pharmaceutical overweight Barclays Capital
27.03.15 Biomarin Pharmaceutical Buy UBS AG
27.03.15 Biomarin Pharmaceutical Buy Deutsche Bank AG
19.12.14 Biomarin Pharmaceutical Outperform RBC Capital Markets
11.12.14 Biomarin Pharmaceutical Buy UBS AG
25.11.14 Biomarin Pharmaceutical Outperform RBC Capital Markets
24.10.14 Biomarin Pharmaceutical Outperform RBC Capital Markets
06.11.12 Biomarin Pharmaceutical outperform RBC Capital Markets
03.09.12 Biomarin Pharmaceutical outperform RBC Capital Markets
28.08.12 Biomarin Pharmaceutical hold Deutsche Bank Securities
23.07.12 Biomarin Pharmaceutical outperform RBC Capital Markets
22.06.12 Biomarin Pharmaceutical outperform RBC Capital Markets
01.06.12 Biomarin Pharmaceutical outperform RBC Capital Markets
17.02.12 Biomarin Pharmaceutical outperform RBC Capital Markets
13.02.12 Biomarin Pharmaceutical outperform RBC Capital Markets
12.12.11 Biomarin Pharmaceutical buy Citigroup Corp.
08.12.11 Biomarin Pharmaceutical buy Citigroup Corp.
07.12.11 Biomarin Pharmaceutical buy Jefferies & Company Inc.
29.09.11 Biomarin Pharmaceutical buy Deutsche Bank Securities
25.10.10 Biomarin Pharmaceutical neutral Wedbush Morgan Securities Inc.
17.08.10 Biomarin Pharmaceutical neutral Wedbush Morgan Securities Inc.
16.04.10 Biomarin Pharmaceutical kaufen Der Aktionär
29.10.09 Biomarin Pharmaceutical outperform Credit Suisse Group
22.10.09 Biomarin Pharmaceutical buy Citigroup Corp.
19.10.09 Biomarin Pharmaceutical hold ROTH Capital Partners, LLC
08.10.09 Biomarin Pharmaceutical buy Jefferies & Company Inc.
03.08.09 Biomarin Pharmaceutical neutral Wedbush Morgan Securities Inc.
31.07.09 Biomarin Pharmaceutical buy Jefferies & Company Inc.